Paolo Tarantino: Our article on Optimizing the Safety of ADCs for their Outlook on Cancer treatment has been published in Nature

Paolo Tarantino shared a post on LinkedIn:

”Grateful to Nature for selecting our article on Optimizing the Safety of ADCs for their Outlook on Cancer treatment.

As a result, the article will be open access for the next 6 months.

Make sure to download a copy if you’re interested in ADCs!”

Source: Paolo Tarantino/LinkedIn

Paolo Tarantino, MD researcher, holds positions at both the European Institute of Oncology in Milan, Italy, and the Dana-Farber Cancer Institute in Boston, MA, Specializing in breast cancer. Currently, Dr. Tarantino is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a robust publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field. Dr. Tarantino’s dedication and innovative approach contribute significantly to the advancement of breast cancer treatment and research.